Pliant Therapeutics, Inc. (PLRX) is a Biotechnology company in the Healthcare sector, currently trading at $1.30. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is PLRX = $3 (+130.8% upside).
Valuation: PLRX trades at a trailing Price-to-Earnings (P/E) of -0.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.03.
Net income is $149M (loss), growing at -11.4%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+38 pp trend).
Balance sheet: total debt is $29M against $181M equity (Debt-to-Equity (D/E) ratio 0.16, conservative). Current ratio is 12 (strong liquidity). Debt-to-assets is 12.9%. Total assets: $225M.
Analyst outlook: 8 / 16 analysts rate PLRX as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 64/100 (Pass), Income ?/100 (Fail).
